CTI BioPharma
| CTI BioPharma | |
|---|---|
| legal form | Incorporated |
| founding | 1992 |
| Seat | Seattle , WA USA |
| management | Adam R. Craig, CEO , Jack W. Singer, Founder and EVP |
| sales | $ 57.4 million (2016) |
| Branch | pharmacy |
| Website | www.ctibiopharma.com |
CTI BioPharma is an American, biotechnological pharmaceutical company that was founded in 1992 as CTI and has been listed on the American technology exchange NASDAQ since 1997 under the label CTIC. Its headquarters are in CTI BioPharma Seattle , Washington . The company specializes in the acquisition , development and marketing of new targeted therapies, primarily in hematology .
Medication
CTI BioPharma has the following drug on the market:
- Pixantrone (trade name in the EU: Pixuvri ; not approved in the US) used to treat adult patients with certain types of non-Hodkin B-cell lymphoma . Pixuvri is marketed by Servier in all markets outside the United States .
The following substances are in (further) clinical development:
- Pixantrone in another form of the NHL
- Pacritinib , a Janus Kinase Inhibitor in Myelofibrosis and
- Tosedostat , a selective, oral inhibitor of aminopeptidases in relapsed / refractory AML / MDS .
Cooperations
CTI BioPharma has a strong strategic focus on cooperation.
- Since 2014, CTI BioPharma has been cooperating with the French pharmaceutical company Servier to market Pixuvri in Europe.
- In June 2017, CTI BioPharma received a milestone payment of $ 10 million from the Israeli pharmaceutical company Teva for achieving milestones in the sales of Trisenox ( arsenic (III) oxide ), a drug that CTI BioPharma at the time sold to - meanwhile bought by Teva - has sold the pharmaceutical company Cephalon . Trisenox has orphan drug status in Europe and is used to treat acute promyelocytic leukemia (APL), a type of acute myeloid leukemia . CTI BioPharma from Teva expected a further $ 10 million as a milestone payment for Trisenox in February 2018.
Web links
Individual evidence
- ↑ a b History ( Memento of the original from May 18, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , Company WebSite, accessed May 23, 2017
- ↑ a b CTI BioPharma Global Headquarters , Company WebSite, accessed on May 23, 2017
- ^ Leadership , Company WebSite, accessed May 23, 2017
- ↑ CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results , PM CTI BioPharma dated March 2, 2017, accessed on May 23, 2017
- ↑ Investor FAQ , Company WebSite, accessed May 23, 2017
- ↑ Overview , Company WebSite, accessed May 23, 2017
- ↑ Approved in the EU , Company WebSite, accessed May 23, 2017
- ↑ Summary of the EPAR for the public , European Medicines Agency (EMA), accessed on May 23, 2017
- ↑ Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI® , PM Servier of April 25, 2017, accessed on May 26, 2017
- ^ Company-Sponsored Trials , Company WebSite, accessed May 23, 2017
- ↑ About Pacritinib , Company WebSite, accessed February 4, 2018
- ↑ Extension granted by CHMP of the EMA for response to Day 120 List of Questions for the MAA for pacritinib , PM CTI BioPharma from January 25, 2018, accessed on February 4, 2018
- ↑ Partnering with CTI BioPharma
- ↑ Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI® , PM CTI BioPharma of April 25, 2017, accessed on May 23, 2017
- ↑ CTI BioPharma Receives $ 10 Million Milestone Payment for TRISENOX® , PM CTI BioPharma, June 15, 2017, accessed July 5, 2017
- ↑ Dietmar P. Berger, Rupert Engelhardt, Roland Mertelsmann : The Red Book: Hematology and Internal Oncology. 4th edition. Hüthig Jehle Rehm, 2011, ISBN 978-3-609-51216-7 , p. 120 ( limited preview in the Google book search).
- ↑ CTI BioPharma to Receive $ 10 Million Milestone Payment for TRISENOX® , PM CTI BioPharma of January 18, 2018, accessed on February 4, 2018
